Body Shortcuts
Company JW, protecting human health and future
Home

History

Fearless of change JW Shinyak walks continuously.
Taking a strong step towards the clinical-to-field 10, we practice the founding principle of " pioneering spirit. "

2024

  • ∙  Develops CAR-NK cell therapy with C&C Research Laboratories & Kure.AI Therapeutics

2023

  • ∙  Exclusive domestic sales agreement with Galderma Korea for hair loss and onychomycosis treatments
  • ∙  Completion of relocation to new headquarters in Gwacheon, strengthening 'R&D-focused' management system
  • ∙  Exclusive sales agreement with Pierre Fabre in France for 'hair strengthening cosmetics'

2022

  • ∙  ISO 37001 certification for international standard anti-corruption management system

2021

  • ∙  Joint research agreement with OncoInsight for 'CAR-M' cancer immunotherapy

2020

  • ∙  Obtainment of the patent registrations for the manufacturing technology of anticancer / autoimmune disease dendritic cell therapy products both in Europe and China

2019

  • ∙  Registered patent for dendritic cell therapy manufacturing technology in USA and Japan

2018

  • ∙  Japanese patent registration for dendritic cell manufacturing method with increased specific gene expression

2017

  • ∙  CreaVax- BC to Approve Clinical 1/2 Phase IND

2016

  • ∙  Change Your Mission to JW Shinyak Company

2015

  • ∙  Vision 70 + 5 Announcement

2014

  • ∙  CreaVax-EMC, Clinical Phase 3 IND Approved

2013

  • ∙  CreaVax-RA approves clinical 2b

2012

  • ∙  Begin Hyangtonsitokain Project

2011

  • ∙  Change Your Mission to JW Global Shinyak Company
  • ∙  Group New CI Pre-Form

2009

  • ∙  Combined New Stock KOSDAQ listing

2008

  • ∙  The Head Office : Daeryoung Technotown, 664 Sasan-dong, Geumcheon-gu, Seoul, 3rd floor

2007

  • ∙  Obtain item approval (CreaVax-SIC) and manufacturing license / KGMP

2005

  • ∙  Mutual to internal and external shinyak
  • ∙  Head Office : 345-30 Ace Line 3, Sasan-dong, Geumcheon-gu, Seoul

2001

  • ∙  A large oil absorption merger
  • ∙  Obtain approval for medical wholesale business (Pyeongtaek Plant)

2000

  • ∙  Purchase a license to manufacture cosmetics (Pyeongtaek Plant)

1996

  • ∙  Purchase a license to manufacture cosmetics (Pyeongtaek Plant)
  • ∙  KGMP qualification certification (Pyeongtaek Plant)

1995

  • ∙  Head Office : 330-11, Sinjeong-dong, Yangcheon-gu, Seoul
  • ∙  Factory relocation : 441-8, Mogok-dong, Pyeongtaek, Gyeonggi-do

1991

  • ∙  Mutual to Deayou Shinyak, Ltd.

1990

  • ∙  The acquisition of the company's regular pharmaceutical company from internal and external constraints.